X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs ASTRAZENECA PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD ASTRAZENECA PHARMA BIOCON LTD/
ASTRAZENECA PHARMA
 
P/E (TTM) x 36.5 90.6 40.3% View Chart
P/BV x 4.9 12.9 37.6% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 BIOCON LTD   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-16
ASTRAZENECA PHARMA
Mar-14
BIOCON LTD/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs4961,285 38.6%   
Low Rs397634 62.5%   
Sales per share (Unadj.) Rs174.3189.6 91.9%  
Earnings per share (Unadj.) Rs44.8-0.2 -22,006.4%  
Cash flow per share (Unadj.) Rs56.93.8 1,480.6%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs202.868.6 295.4%  
Shares outstanding (eoy) m200.0025.00 800.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.65.1 50.6%   
Avg P/E ratio x10.0-4,712.7 -0.2%  
P/CF ratio (eoy) x7.8249.6 3.1%  
Price / Book Value ratio x2.214.0 15.7%  
Dividend payout %11.20-   
Avg Mkt Cap Rs m89,22023,988 371.9%   
No. of employees `0004.41.6 283.2%   
Total wages/salary Rs m6,3631,605 396.5%   
Avg. sales/employee Rs Th7,894.53,040.2 259.7%   
Avg. wages/employee Rs Th1,441.21,029.2 140.0%   
Avg. net profit/employee Rs Th2,029.7-3.3 -62,166.2%   
INCOME DATA
Net Sales Rs m34,8544,740 735.4%  
Other income Rs m84592 917.5%   
Total revenues Rs m35,6994,832 738.8%   
Gross profit Rs m8,200-130 -6,317.4%  
Depreciation Rs m2,423101 2,394.3%   
Interest Rs m1020-   
Profit before tax Rs m6,520-139 -4,694.0%   
Minority Interest Rs m-7440-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5,754139 4,142.5%   
Tax Rs m2,5695 50,471.5%   
Profit after tax Rs m8,961-5 -176,051.1%  
Gross profit margin %23.5-2.7 -859.1%  
Effective tax rate %39.4-3.7 -1,075.2%   
Net profit margin %25.7-0.1 -23,940.8%  
BALANCE SHEET DATA
Current assets Rs m39,9322,726 1,464.6%   
Current liabilities Rs m16,2762,435 668.4%   
Net working cap to sales %67.96.1 1,104.0%  
Current ratio x2.51.1 219.1%  
Inventory Days Days5474 72.6%  
Debtors Days Days8641 211.4%  
Net fixed assets Rs m39,1011,035 3,776.8%   
Share capital Rs m1,00050 2,000.0%   
"Free" reserves Rs m38,591942 4,095.0%   
Net worth Rs m40,5561,716 2,363.4%   
Long term debt Rs m20,7240-   
Total assets Rs m84,8164,156 2,040.8%  
Interest coverage x64.9NM-  
Debt to equity ratio x0.50-  
Sales to assets ratio x0.41.1 36.0%   
Return on assets %10.7-0.1 -8,724.7%  
Return on equity %22.1-0.3 -7,449.0%  
Return on capital %19.00-  
Exports to sales %30.75.7 539.4%   
Imports to sales %20.46.5 315.4%   
Exports (fob) Rs m10,717270 3,966.3%   
Imports (cif) Rs m7,105306 2,319.6%   
Fx inflow Rs m11,789375 3,147.1%   
Fx outflow Rs m8,393470 1,785.2%   
Net fx Rs m3,396-96 -3,554.2%   
CASH FLOW
From Operations Rs m5,264-8 -64,987.7%  
From Investments Rs m-9,540-146 6,547.7%  
From Financial Activity Rs m10,867862 1,260.4%  
Net Cashflow Rs m6,591709 930.3%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 75.0 27.5%  
Indian inst/Mut Fund % 8.4 0.3 2,800.0%  
FIIs % 10.7 15.7 68.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 9.1 218.7%  
Shareholders   109,995 12,856 855.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SHASUN PHARMA  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Recovery of Global Markets, Apex Frozen Food IPO & Cues to Watch Out Today(Pre-Open)

Indian stock markets remained range-bound in lacklustre trade on Tuesday as market participants kept to the sidelines in the absence of clear triggers.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Aug 22, 2017 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS